As the focus shifts to precision medicine, there is increasing prioritization of intervening before disease inception and early intervention as these will allow for disease prevention and/or prompt treatment with therapies with improved side-effect profiles and enhanced efficacy. Given this, we sought to define factors that could predict disease onset within inflammatory bowel disease (IBD) using an Ashkenazi Jewish (AJ) population who carry a 4-fold increased risk of IBD. We began with an examination of genetic factors, using polygenic risk scores (PRS).